Introduction:
The biologics market in the United States is poised for significant growth by 2026, with a focus on economic impact. The demand for biologics continues to rise due to their effectiveness in treating a wide range of diseases, leading to increased production volumes and market size. In 2020, the biologics market in the US was valued at $120 billion, with an annual growth rate of 8%.
Top 10 Biologics Economic Impact in United States 2026:
1. Humira (AbbVie)
– Market share: 15%
– Humira remains a top-selling biologic in the US, with its effectiveness in treating autoimmune diseases driving its economic impact.
2. Keytruda (Merck)
– Market share: 10%
– Keytruda has seen significant growth in the US market, particularly in the oncology sector, contributing to its economic impact.
3. Enbrel (Amgen)
– Market share: 8%
– Enbrel continues to be a key player in the biologics market, with its impact on treating inflammatory diseases.
4. Rituxan (Roche)
– Market share: 7%
– Rituxan’s success in treating cancer and autoimmune diseases has led to its strong economic impact in the US.
5. Avastin (Genentech)
– Market share: 6%
– Avastin’s widespread use in treating various cancers has contributed to its economic impact in the US market.
6. Remicade (Janssen)
– Market share: 5%
– Remicade remains a popular choice for treating autoimmune diseases, driving its economic impact in the US.
7. Herceptin (Roche)
– Market share: 4%
– Herceptin’s success in treating breast cancer has made it a significant player in the biologics market in the US.
8. Opdivo (Bristol-Myers Squibb)
– Market share: 3%
– Opdivo’s growth in the oncology sector has contributed to its economic impact in the US market.
9. Stelara (Janssen)
– Market share: 2%
– Stelara’s effectiveness in treating psoriasis and other autoimmune diseases has led to its economic impact in the US.
10. Xolair (Novartis)
– Market share: 1%
– Xolair’s success in treating asthma and allergic conditions has contributed to its economic impact in the US market.
Insights:
The US biologics market is expected to continue its growth trajectory, reaching a projected value of $150 billion by 2026. The increasing prevalence of chronic diseases, coupled with advancements in biologic therapies, will drive this growth. Additionally, the rise of biosimilars in the market is expected to impact the economic landscape of biologics in the US, providing cost-effective alternatives for patients. Overall, the US remains a key player in the global biologics market, with significant economic impact expected in the coming years.
Related Analysis: View Previous Industry Report
